A5 (Iclusig 15 mg)

Generic Name: ponatinib

Pill imprint A5 has been identified as Iclusig 15 mg.

Iclusig is used in the treatment of chronic myelogenous leukemia; acute lymphoblastic leukemia and belongs to the drug classes BCR-ABL tyrosine kinase inhibitors, multikinase inhibitors, VEGF/VEGFR inhibitors. There is positive evidence of human fetal risk during pregnancy. Iclusig 15 mg is not subject to the Controlled Substances Act.

See also related documents.

Imprint Search

Images for A5

Iclusig 15 mg A5
Iclusig
Generic Name:
ponatinib
Imprint:
A5
Strength:
15 mg
Color:
White
Shape:
Round
Availability:
Prescription only
Drug Class:
BCR-ABL tyrosine kinase inhibitors
Multikinase inhibitors
VEGF/VEGFR inhibitors
Pregnancy Category:
D - Positive evidence of risk
CSA Schedule:
N - Not a controlled drug
Manufacturer:
ARIAD Pharmaceuticals, Inc.
National Drug Code (NDC):
76189-0535
Inactive Ingredients:
lactose monohydrate
microcrystalline cellulose
silicon dioxide
magnesium stearate

View Details Print Page

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 2014 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.

Hide
(web5)